In Segment A, participants will obtain different doses and schedules of oral ABBV-744 tablet to recognize Risk-free dosing program. Extra members will probably be enrolled for the discovered monotherapy dosign regimen. In Segment B, individuals will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "add-on" therapy. In Segment https://steveno887dpa1.wikimeglio.com/user